Grand Life Sciences
Headquartered in Chengdu, China, Grand Life Sciences Group is dedicated to driving global innovation and excellence in the life sciences industry.
Grand Life Sciences is a leading innovator in five key sectors: blood products, probiotics, vaccines, medical nutrition, and perioperative care solutions. With a focus on cutting-edge technologies in global drug research and development, we strategically build a distinctive product portfolio centered on clinical value and forward-looking insights.
Our operations include four R&D centers and nine core technology platforms located in Beijing, Chengdu, Nanjing, Wuhan, and Hangzhou. We have achieved 9 pharmaceutical breakthroughs and currently have over 30 innovative products in clinical development, continuously driving innovation and propelling the company's growth.
Our state-of-the-art production facilities, located in nearly 10 cities across China, are built to the highest standards and adhere to rigorous quality management protocols. With a robust sales network covering every province and city across the country, we serve hundreds of thousands of end users. Additionally, our plasma products are in high demand globally, with exports to more than 20 countries, as we accelerate our efforts to expand into international markets.
We are at the forefront of innovation in the blood products industry, advancing R&D capabilities from plasma sourcing to cutting-edge recombinant technology platforms. Our comprehensive product portfolio spans three major categories: albumin, immunoglobulin, and coagulation factors. Recognized as one of China’s leading companies in the blood product sector, we boast the highest plasma utilization rate, the most diverse product range, and the most comprehensive specifications in the market.
Our state-of-the-art manufacturing facility represents an internationally leading hub for blood product production, capable of meeting diverse market demands across the full product spectrum. This positions us as a global leader in the industrialization of blood products.
In addition, we hold exclusive domestic commercialization rights to KN057, a groundbreaking monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) for the treatment of hemophilia. KN057 has successfully entered two Phase III clinical trials in China and was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) in 2024.
We have established a proprietary library of tens of thousands of functional microbial strains and are actively advancing next-generation live biotherapeutic products. Our core subsidiary, Hangzhou Yuanda Healthcare, specializes in gastrointestinal health and metabolic disorders. With the completion of its new facility, it is poised to become Asia’s largest fermentation site, offering the most extensive portfolio of commercial strains and setting new standards for automation and connectivity in live biotherapeutic drug manufacturing.
Our flagship product, Quadruple Bifidobacterium Tablets (brand name: Siliankang®), consistently maintains a leading market share and is highly recommended in clinical treatment guidelines. In the metabolic domain, we are developing HZBio1, a Class I innovative drug for the treatment of hyperuricemia with gout, which is currently in Phase II clinical trials.
We have built a fully integrated, international platform encompassing research, development, production, and sales. This platform includes four proprietary R&D platforms specializing in recombinant proteins, novel adjuvants, bacterial vaccines, and next-generation vaccine technologies, supporting a robust pipeline of over ten innovative vaccine candidates.
A key milestone in 2024 was the advancement of our independently developed therapeutic recombinant hepatitis B vaccine into Phase II clinical trials. This marked the first innovative therapeutic hepatitis B vaccine in China approved for clinical trials in individuals aged 18 and older.
In addition, we are constructing a state-of-the-art vaccine industrialization base in Hangzhou, designed to meet the highest global standards. Once operational, this facility will enable the commercial production of eight to ten advanced vaccines, with an anticipated annual output value exceeding RMB 10 billion.
In the perioperative care sector, we have developed extensive expertise in hemostasis and pain management. Our flagship product, Hemocoagulase Bothrops Atrox (brand name: Baquting®), has consistently held a leading market share. In 2024, we introduced Recombinant Human Thrombin (brand name: Zepuning®), the first and only recombinant human thrombin in China developed using gene recombination technology, further solidifying our leadership in the hemostasis field.
With exclusive domestic sales rights and a robust product portfolio, we continue to strengthen our presence in hemostasis. In pain management, our pipeline includes innovative products such as Collagenase for Injection, a Class I innovative drug, and Collagenase Ointment, a unique product in the Chinese market.
As we rapidly expand our market presence, we are also conducting extensive post-market research to explore new indications and patient groups, unlocking additional potential for our core product line and delivering enhanced value to healthcare providers and patients alike.
In the medical nutrition sector, we utilize our advanced lipid emulsion complex formulation platform to address the growing clinical needs arising from an aging population and the increasing prevalence of chronic conditions such as cancer. Our efforts are focused on building a comprehensive pipeline encompassing amino acids, parenteral nutrition, and full-cycle nutritional management solutions.
To date, we have initiated more than ten innovative drug development projects, with industrialization efforts progressing rapidly. By combining cutting-edge research with scalable production capabilities, we are committed to delivering advanced nutritional solutions to improve patient outcomes and support healthcare providers worldwide.